Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Operating Expenses (2016 - 2025)

Adma Biologics' Other Operating Expenses history spans 13 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 9.6% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $5.0 million, up 7.53%, while the annual FY2025 figure was $5.0 million, 7.49% up from the prior year.
  • Other Operating Expenses reached $1.2 million in Q4 2025 per ADMA's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $5.3 million in Q4 2022 to a low of $646000.0 in Q3 2023.
  • Average Other Operating Expenses over 5 years is $2.3 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Other Operating Expenses: soared 110.58% in 2021, then tumbled 87.18% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $4.3 million in 2021, then increased by 23.16% to $5.3 million in 2022, then crashed by 83.44% to $872000.0 in 2023, then skyrocketed by 49.31% to $1.3 million in 2024, then fell by 9.6% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Other Operating Expenses are $1.2 million (Q4 2025), $1.3 million (Q3 2025), and $1.2 million (Q2 2025).